Search Results - "Blanchette, Phillip S."

Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline by Dhesy-Thind, Sukhbinder, Fletcher, Glenn G, Blanchette, Phillip S, Clemons, Mark J, Dillmon, Melissa S, Frank, Elizabeth S, Gandhi, Sonal, Gupta, Rasna, Mates, Mihaela, Moy, Beverly, Vandenberg, Ted, Van Poznak, Catherine H

“…Purpose To make recommendations regarding the use of bisphosphonates and other bone-modifying agents as adjuvant therapy for patients with breast cancer…”
Get full text

Antibody-Drug Conjugates in Breast Cancer: Ascent to Destiny and Beyond-A 2023 Review by Xiao, Tian, Ali, Sanji, Mata, Danilo Giffoni M M, Lohmann, Ana Elisa, Blanchette, Phillip S

“…Antibody-drug conjugates (ADCs) are revolutionizing cancer treatment, adding another important new class of systemic therapy. ADCs are a specially designed…”
Get full text

Genomic testing in cancer: Patient knowledge, attitudes, and expectations by Blanchette, Phillip S., Spreafico, Anna, Miller, Fiona A., Chan, Kelvin, Bytautas, Jessica, Kang, Steve, Bedard, Philippe L., Eisen, Andrea, Potanina, Larissa, Holland, Jack, Kamel‐Reid, Suzanne, McPherson, John D., Razak, Albiruni R., Siu, Lillian L.

“…BACKGROUND Genomic testing in cancer (GTC) characterizes genes that play an important role in the development and growth of a patient's cancer. This form of…”
Get full text

The association between endocrine therapy use and osteoporotic fracture among post-menopausal women treated for early-stage breast cancer in Ontario, Canada by Blanchette, Phillip S., Lam, Melody, Le, Britney, Richard, Lucie, Shariff, Salimah Z., Ouédraogo, Alexandra M., Pritchard, Kathleen I., Raphael, Jacques, Vandenberg, Ted, Fernandes, Ricardo, Desautels, Danielle N., Chan, Kelvin K.W., Earle, Craig C.

“…The use of endocrine therapy for early-stage breast cancer, particularly aromatase inhibitor therapy has been associated with an increased risk of osteoporosis…”
Get full text

Do aromatase inhibitors increase cardiovascular risk? Piecing together the evidence by Desautels, Danielle N., MD FRCPC, Blanchette, Phillip S., MD FRCPC, Pritchard, Kathleen I., MD FRCPC

Get full text

Treatment and Mortality Following Cancer Diagnosis Among People With Non-affective Psychotic Disorders in Ontario, Canada: A Retrospective Cohort Study by Wootten, Jared C, Richard, Lucie, Lam, Melody, Blanchette, Phillip S, Solmi, Marco, Anderson, Kelly K

“…People with psychotic disorders have a higher risk of mortality following cancer diagnosis, compared to people without psychosis. The extent to which this…”
Get full text

Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update by Eisen, Andrea, Somerfield, Mark R, Accordino, Melissa K, Blanchette, Phillip S, Clemons, Mark J, Dhesy-Thind, Sukhbinder, Dillmon, Melissa S, D'Oronzo, Stella, Fletcher, Glenn G, Frank, Elizabeth S, Hallmeyer, Sigrun, Makhoul, Issam, Moy, Beverly, Thawer, Alia, Wu, Joy Y, Van Poznak, Catherine H

“…To update recommendations of the American Society of Clinical Oncology (ASCO)-Ontario Health (Cancer Care Ontario [CCO]) adjuvant bone-modifying agents in…”
Get full text

Cancer incidence and stage at diagnosis among people with psychotic disorders: Systematic review and meta-analysis by Wootten, Jared C., Wiener, Joshua C., Blanchette, Phillip S., Anderson, Kelly K.

“…Research regarding the incidence of cancer among people with psychotic disorders relative to the general population is equivocal, although the evidence…”
Get full text

Cancer incidence and stage at diagnosis among people with recent‐onset psychotic disorders: A retrospective cohort study using health administrative data from Ontario, Canada by Wootten, Jared C., Richard, Lucie, Blanchette, Phillip S., Wiener, Joshua C., Anderson, Kelly K.

“…Objective Prior evidence on the relative risk of cancer among people with psychotic disorders is equivocal. The objective of this study was to compare…”
Get full text

Utilization of Immunotherapy in Patients with Cancer Treated in Routine Care Settings: A Population-Based Study Using Health Administrative Data by Raphael, Jacques, Richard, Lucie, Lam, Melody, Blanchette, Phillip S, Leighl, Natasha B, Rodrigues, George, Trudeau, Maureen E, Krzyzanowska, Monika K

“…The introduction of immunotherapy (IO) in the treatment of patients with cancer has significantly improved clinical outcomes. Population level information on…”
Get full text

The safety of seasonal influenza vaccination among adults prescribed immune checkpoint inhibitors: A self-controlled case series study using administrative data by Grima, Alicia A., Kwong, Jeffrey C., Richard, Lucie, Reid, Jennifer, Raphael, Jacques, Basta, Nicole E., Carignan, Alex, Top, Karina A., Brousseau, Nicholas, Blanchette, Phillip S., Sundaram, Maria E.

“…Immune checkpoint inhibitor (ICI) therapy for patients undergoing cancer treatment carries a risk of severe immune-related adverse events (IRAEs). Questions…”
Get full text

Influenza Vaccine Effectiveness Among Patients With Cancer: A Population-Based Study Using Health Administrative and Laboratory Testing Data From Ontario, Canada by Blanchette, Phillip S, Chung, Hannah, Pritchard, Kathleen I, Earle, Craig C, Campitelli, Michael A, Buchan, Sarah A, Schwartz, Kevin L, Crowcroft, Natasha S, Gubbay, Jonathan B, Karnauchow, Timothy, Katz, Kevin, McGeer, Allison J, McNally, James D, Richardson, David C, Richardson, Susan E, Rosella, Laura C, Simor, Andrew, Smieja, Marek, Zahariadis, George, Campigotto, Aaron, Kwong, Jeffrey C

“…Seasonal influenza vaccination is recommended for patients with cancer despite concerns of disease or treatment-associated immunosuppression. The objective of…”
Get full text

Everolimus in Advanced Breast Cancer: A Systematic Review and Meta-analysis by Raphael, Jacques, Lefebvre, Cory, Allan, Alison, Helou, Joelle, Boldt, Gabriel, Vandenberg, Theodore, Blanchette, Phillip S

“…Background Everolimus plus exemestane is approved for the treatment of hormone receptor-positive metastatic breast cancer (MBC) after progression on…”
Get full text

Factors associated with endocrine therapy adherence among post-menopausal women treated for early-stage breast cancer in Ontario, Canada by Blanchette, Phillip S., Lam, Melody, Richard, Lucie, Allen, Britney, Shariff, Salimah Z., Vandenberg, Ted, Pritchard, Kathleen I., Chan, Kelvin K. W., Louie, Alexander V., Desautels, Danielle, Raphael, Jacques, Earle, Craig C.

“…Purpose Adherence to adjuvant endocrine therapy among post-menopausal breast cancer patients is an important survivorship care issue. We explored factors…”
Get full text

Bone-Targeted Therapy in Early Breast Cancer by Jerzak, Katarzyna J, Raphael, Jacques, Desautels, Danielle N, Blanchette, Phillip S, Tyono, Ivan, Pritchard, Kathleen I

“…Aromatase inhibitors (AIs) play an important role in the adjuvant treatment of hormone receptor-positive breast cancer, but they are associated with bone loss…”
Get more information

The role of bisphosphonates in early- and advanced-stage breast cancer: have we finally optimized care? by Blanchette, Phillip S, Pritchard, Kathleen I

“…Bisphosphonates have played an important role in the treatment of breast cancer, mainly in patients with bone metastasis, by reducing the risk of fracture,…”
Get more information

The association between endocrine therapy use and dementia among post-menopausal women treated for early-stage breast cancer in Ontario, Canada by Blanchette, Phillip S., Lam, Melody, Le, Britney, Richard, Lucie, Shariff, Salimah Z., Pritchard, Kathleen I., Raphael, Jacques, Vandenberg, Ted, Fernandes, Ricardo, Desautels, Danielle, Chan, Kelvin K.W., Earle, Craig C.

“…The association between endocrine therapy and risk of dementia remains uncertain. We investigated the association between adjuvant endocrine therapy for breast…”
Get full text

Adjuvant endocrine therapy for breast cancer: longer therapy and the need for personalized treatment--should we treat beyond the data? by Blanchette, Phillip S, Pritchard, Kathleen I

Get more information

Factors associated with acute kidney injury among patients with cancer treated with immune checkpoint inhibitor therapy: A population-based study by Blanchette, Phillip S., Richard, Lucie, Shariff, Salimah, Raphael, Jacques, Earle, Craig, Garg, Amit, Kitchlu, Abhijat

“…2584 Background: Cancer immune checkpoint inhibitor (ICI) therapy may be associated with kidney immune-related adverse events (IRAEs) and other causes of acute…”
Get full text

The safety of seasonal influenza vaccination among patients prescribed immune checkpoint inhibitors: A self-controlled case series study using administrative data by Grima, Alicia Ann, Kwong, Jeff C, Richard, Lucie, Raphael, Jacques, Basta, Nicole, Carignan, Alex, Top, Karin, Brousseau, Nicholas, Blanchette, Phillip S., Sundaram, Maria

“…6606 Background: Immune checkpoint inhibitor (ICI) therapy for cancer patients carries a risk of severe immune-related adverse events (IRAEs). Since vaccines…”
Get full text